Ocaliva
PreclinicalSmall molecule
Ocaliva is one of 10 small molecule programs targeting Primary Biliary Cholangitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Primary Biliary Cholangitis
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Ocaliva
IIntercept Pharmaceuticals
Approved
Iqirvo
IpsenPhase 3
Tricor
JJagotec
Phase 3
Lipaglyn
ZZydus Therapeutics Inc.
Phase 3
Selincro
IIndivior Inc.
Phase 2
CS0159
CCascade Pharmaceuticals, Inc
Phase 3
Seladelpar
GileadPhase 3
Volixibat
MMirum Pharmaceuticals, Inc.
Phase 2
Ocaliva
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ocaliva. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details